Asia
The portfolio consists of acute, chronic and oncology products.
Teva has made a target of cutting costs by $3B by the end of 2019.
Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.
3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.
Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.
East Sunshine Foresight Fund will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents.
The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.
Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
Will this new buy be enough for Celgene investors?
PRESS RELEASES